We will make headway into the global market beyond the domestic market by gathering the ability of JW.
-Lead compound selectively and directly inhibits XBP1s-Supported by research funding for two y...
-STAT3 Inhibitor JW2286 Developed as a First-in-Class Global Innovative Drug-Expected to Addre...
-First Efficacy Evaluation on Human Skin Organoids and Androgenic Alopecia Animal Model Reveal...
-Discovered through the new drug development platform ‘JWELRY,’ targeting the Wnt signaling pa...
-DSMB's primary evaluation based on safety data from gout patients is positive-Accelerating Ph...
-Phase 3 IND approvals completed in 5 Asian countries, including Korea... Efficacy in reducing...
-Optimization of Lead Compounds for Direct STAT6 Inhibition-Utilization of XtalPi’s AI Drug De...
-Supplying 'WINUF Central 736·1085ml' through Mongolian pharmaceutical company AsiaPharma LLC-...
-Wnt pathway activation via GFRA1 receptor binding is a key action mechanism of hair regeneration…Fi...
- ‘First in Korea', it has formed a partnership with Venture Capital firm ARCH Venture Partners of U...